Griffen is an attorney in Harris Sliwoski’s Los Angeles office, where he focuses his practice on corporate, transactional, intellectual property, data security, regulatory, and litigation matters across a wide variety of domestic and international industries.
Click HERE to register for our upcoming FREE Q&A webinar on ketamine regulations and the future of therapeutic psychedelic medicines! In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that
Over the last year and change, I’ve written quite a bit about how the ketamine telehealth industry was in store for a rude awakening when the COVID-19 public health emergency (PHE) declaration ended. My most recent post, entitled “Bad News for Ketamine Telehealth” predicted an imminent shakeup in the industry due to the looming end
Last summer, my colleague, Ethan Minkin, published a post entitled “Utah Ketamine Clinics Face New Patient Monitoring Law.” The law in question applied a host of new requirements on anesthesia or sedation providers, which created a series of hurdles for ketamine clinics. A few weeks ago, a Utah state legislator submitted a bill that would
Earlier this week, President Joe Biden’s administration made an announcement that signals potential bad news for the ketamine telehealth industry. Effective May 11, 2023, the federal COVID-19 public health emergency (PHE) declaration will end. This is likely to plunge the entire ketamine telehealth industry into chaos in the coming months. If you are unfamiliar with
Since Denver became the first U.S. jurisdiction to decriminalize psilocybin in 2019, a number of cities across the country – including, most notably, Oakland and Santa Cruz in California – have decriminalized psychedelics in various forms. And as readers of the Psychedelics Law Blog are surely aware, Oregon and now Colorado passed full-scale regulatory regimes.
There’s been a lot of news about Tuesday’s election. One of the things that hasn’t made the waves is Colorado’s approval of Prop. 122, which will pave the way for psilocybin clinics like in Oregon. Prop. 122 is actually much broader than Oregon’s Measure 109, and legalizes psychedelics far beyond just psilocybin. Many expressed opposition
Last week, we presented a psychedelics webinar entitled “How to Protect Your Psychedelics Business.” The panelists were Paul Coble from our Phoenix office), me (Griffen Thorne from our Los Angeles office), and Graham Pechenik of Calyx Law in San Francisco. In the webinar, we presented on business law and intellectual property issues that will affect
Next month, Colorado voters will decide the fate of Proposition 122, named the Natural Medicine Health Act of 2022 (NMHA). If passed, NHMA would legalize a host of psychedelics in Colorado. Today, we’ll look at what NMHA would do. Natural Medicine Health Act of 2022 NMHA is modeled on – or at least influenced by
Our psychedelics team routinely fields questions from non-Oregon residents looking for Oregon psilocybin licenses. However, one of Measure 109‘s more infamous requirements is its residency requirement. These provisions require that, until January 1, 2025, manufacturing facilities and service centers must have majority ownership by individual(s) who have resided in Oregon for at least two years.
In early 2020, the United States Department of Health and Human Services (DHHS) declared a public health emergency (PHE) due to the COVID-19 pandemic. DHHS extended the PHE numerous times over the last few years, most recently on July 15, 2022 for a period of 90 days. The PHE will expire on October 13, 2022
